The ESMO Tumour-Agnostic Classifier and Screener (ETAC-S): a tool for assessing tumour-agnostic potential of molecularly guided therapies and for steering drug development

C. Benedikt Westphalen; Diogo Martins-Branco; Juliana Rodrigues Beal; Claudia Cardone; N. Coleman; Alison M. Schram; Susan Halabi; Stefan Michiels; Christina Yap; Fabrice André; Frédéric Bibeau; Giuseppe Curigliano; Elena Garralda; Shivaani Kummar; Razelle Kurzrock; Sewanti Limaye; Sonja Loges; Aurélien Marabelle; Caterina Marchiò; Joaquı́n Mateo; Jordi Rodón; Tanja Španić; George Pentheroudakis; Vivek Subbiah

doi:10.1016/j.annonc.2024.07.730

Ask about this paper

Answers are grounded in this paper and cite their sources.

Abstract

Advances in precision oncology led to approval of tumour-agnostic molecularly guided treatment options (MGTOs). The minimum requirements for claiming tumour-agnostic potential remain elusive.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Westphalen et al. (2024) studied this question.

synapsesocial.com/papers/68e5b019b6db64358754943c https://doi.org/10.1016/j.annonc.2024.07.730

View Full Paper

Ask AI

Bookmark

Share

The ESMO Tumour-Agnostic Classifier and Screener (ETAC-S): a tool for assessing tumour-agnostic potential of molecularly guided therapies and for steering drug development

Ask about this paper

Abstract

Discussion

Cite This Study

The ESMO Tumour-Agnostic Classifier and Screener (ETAC-S): a tool for assessing tumour-agnostic potential of molecularly guided therapies and for steering drug development

Ask about this paper

Abstract

Discussion

Cite This Study

Keep reading

Keep reading